NIFTY 50
22,828.55 (1.92%)
NIFTY IT
32,740.85 (0.69%)
NIFTY AUTO
20,548.65 (2.03%)
NIFTY FINANCIAL SERVICES
24,555.55 (1.75%)
NIFTY BANK
51,002.35 (1.52%)
NIFTY REALTY
790.15 (1.26%)
NIFTY ENERGY
32,411.10 (2.70%)
NIFTY METAL
8,168.30 (4.09%)
NIFTY FMCG
55,741.10 (0.86%)
NIFTY HEALTH CARE
13,326.65 (1.53%)
NIFTY PHARMA
20,461.90 (2.43%)
NIFTY MEDIA
20,461.90 (2.43%)
Platforms
Mobile Application
Web Trading
Desktop Application
Insights
Research
Videos
Markets
Equity
Derivatives
IPO
Other Markets
Corporate Information
Pricing
Support
Login
Open an Account
Home
Platform
Insights
Research
Markets
Pricing
Support
Login
Open an Account
Trend of Stock Market
A trend is the broad upward or downward movement of a stock's price over time
Forthcoming IPO
Open Issues
Closed Issue
Top Gainers / Losers
52 Weeks High/ Low
Value / Volume Toppers
Get Quotes
Nifty Futures
Top Traded Quantity
Top Traded Value
Derivative Summary
Daily Settlement Price
List Of Underlying
Put Call Ratio
FII Statistics
Most Active Contract
All Index Futures
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Most Active Calls
Most Active Put
Top Gainers
Top Losers
Highest In OI
Lowest In OI
Increase In OI
Decrease In OI
Forthcoming Issues
Open Issues
Closed Issue
World Indices
ADR Prices
MF Investment
FII Investment
Get Quotes
Company Snapshot
Company Background
Board of Directors
Directors Reports
Profit & Loss
Balance Sheet
Quarterly Results
Shareholding Pattern
Key Financial Ratios
Mutual Fund Holdings
Peer Comparison
Technical Chart
Company News
Change Company Name
Lupin Ltd
Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
500257
ISIN Demat
INE326A01037
Book Value
481.38
NSE Symbol
LUPIN
Dividend Yield (%)
0.41
Market Cap (
₹
Cr.)
89,899.94
P/E
28.74
EPS
68.52
Face Value
2
Date
Headline
21-Mar-25
Lupin allots 24,101 equity shares under ESOP
17-Mar-25
Lupin receives USFDA tentative approval for Amifampridine Tablets
07-Mar-25
Lupin launches Rivaroxaban Tablets USP, 2.5 mg in the US
27-Feb-25
Lupin allots 59,940 equity shares under ESOP
21-Feb-25
Lupin receives EIR for its Somerset facility
19-Feb-25
Lupin receives 'A-' leadership rating from CDP
12-Feb-25
Board of Lupin approves transfer of OTC consumer healthcare biz to new subsidiary
10-Feb-25
Lupin and Natco receives USFDA approval for Bosentan Tablets for Oral Suspension
28-Jan-25
Lupin announces board meeting date
08-Jan-25
Lupin receives Establishment Inspection Report for its Pithampur Unit-1
Prev
1
2
3
Next